1921
Volume 68, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The World Health Organization (WHO) has developed guidelines for antimalarial drug efficacy testing for and in areas with low-to-moderate transmission, such as the Americas. These guidelines are used widely by ministries of health and national malaria control programs to assess the efficacy of their first-line and second-line drugs for the treatment of malaria and to provide the information necessary to update national malaria treatment policies. Following the WHO guidelines, we have conducted efficacy trials with a variety of drugs and drug combinations against and at 13 sites in Peru, Bolivia, and Ecuador. Based on these experiences, we have identified several modifications that we believe should be made in the WHO recommendations to make them more suitable to the relatively low levels of transmission in the Americas and to the logistic challenges of carrying out such studies in sparsely populated areas, such as the Amazon Basin. These include changes in inclusion and exclusion criteria, in enrollment and follow-up procedures, and in the measurement of study outcomes.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2003.68.391
2003-04-01
2017-11-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/68/4/0680391.html?itemId=/content/journals/10.4269/ajtmh.2003.68.391&mimeType=html&fmt=ahah

References

  1. World Health Organization, 1996. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO Document No. WHO/MAL/96.1077. Geneva: WHO.
  2. Khoromana CO, Campbell CC, Wirima JJ, Heymann DL, 1986. In vivo efficacy of chloroquine treatment for Plasmodium falciparum in Malawian children under five years of age. Am J Trop Med Hyg 35 : 465–471.
  3. Brandling-Bennett AD, Oloo AJ, Watkins WM, Boriga DA, Kariuki DM, Collins WE, 1988. Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance. Trans R Soc Trop Med Hyg 82 : 833–837.
  4. Bloland PB, Lackritz EM, Kazembe PN, Were JBO, Steketee R, Campbell CC, 1993. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167 : 932–937.
  5. Ringwald P, Ekobo AS, Keundjian A, Mangamba DK, Basco LK, 2000. Chimiorésistance de P. falciparum en milieu urbain á Yaoundé, Cameroun: Part I. surveillance in vitro et in vivo de la résistance de Plasmodium falciparum á la chloroquine entre 1994 et 1999 á Yaoundé. Cameroun. Trop Med Int Health 6 : 92–98.
  6. Barat LM, Himonga B, Nkunika S, Ettling M, Ruebush TK, Kapelwa W, Bloland PB, 1998. A systematic approach to the development of a rational malaria treatment policy in Zambia. Trop Med Int Health 3 : 535–542.
  7. East Africa Network for Monitoring Antimalarial Treatment, 2001. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Trop Med Int Health 6 : 1–8.
  8. Pan American Health Organization, 1998. Evaluation of the therapeutic efficacy of drugs for the treatment of uncomplicated Plasmodium falciparum malaria in the Americas. OPS/HCP/ HCT/113/98. Washington, DC, Pan American Health Organization.
  9. Lemeshow S, Tabor S, 1991. Lot quality assurance sampling: single- and double-sampling plans. World Health Stat Q 44 : 115–132.
  10. Lwanga SK, Lemeshow S, 1991. Sample side determination in health studies: a practical manual. Geneva: World Health Organization.
  11. Bruce-Chwatt LJ, 1986. Chemotherapy of malaria, 2nd ed. World Health Organization Monograph Series No. 27. Geneva: World Health Organization.
  12. Ministerio de Salud, 2000. Programa de Control de Malaria y Otras Enfermedades Metaxénicas, Lima, Peru.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2003.68.391
Loading
/content/journals/10.4269/ajtmh.2003.68.391
Loading

Data & Media loading...

  • Received : 20 Apr 2002
  • Accepted : 07 Oct 2002

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error